NZ535146A - Genetic products differentially expressed in tumors and use thereof - Google Patents

Genetic products differentially expressed in tumors and use thereof

Info

Publication number
NZ535146A
NZ535146A NZ535146A NZ53514603A NZ535146A NZ 535146 A NZ535146 A NZ 535146A NZ 535146 A NZ535146 A NZ 535146A NZ 53514603 A NZ53514603 A NZ 53514603A NZ 535146 A NZ535146 A NZ 535146A
Authority
NZ
New Zealand
Prior art keywords
nucleic acid
tumor
associated antigen
functional fragment
antibody
Prior art date
Application number
NZ535146A
Other languages
English (en)
Inventor
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of NZ535146A publication Critical patent/NZ535146A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
NZ535146A 2002-03-13 2003-03-12 Genetic products differentially expressed in tumors and use thereof NZ535146A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10211088A DE10211088A1 (de) 2002-03-13 2002-03-13 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PCT/EP2003/002556 WO2003076631A2 (de) 2002-03-13 2003-03-12 Differentiell in tumoren exprimierte genprodukte und deren verwendung

Publications (1)

Publication Number Publication Date
NZ535146A true NZ535146A (en) 2006-06-30

Family

ID=27771250

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535146A NZ535146A (en) 2002-03-13 2003-03-12 Genetic products differentially expressed in tumors and use thereof

Country Status (14)

Country Link
US (8) US7429461B2 (OSRAM)
EP (18) EP1483389B1 (OSRAM)
JP (5) JP4963778B2 (OSRAM)
KR (4) KR20120127536A (OSRAM)
CN (4) CN1646692A (OSRAM)
AU (2) AU2003219045B2 (OSRAM)
CA (3) CA2813780C (OSRAM)
DE (1) DE10211088A1 (OSRAM)
ES (3) ES2559079T3 (OSRAM)
IL (4) IL163900A0 (OSRAM)
MX (1) MXPA04008867A (OSRAM)
NZ (1) NZ535146A (OSRAM)
PL (1) PL215160B1 (OSRAM)
WO (1) WO2003076631A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2004018999A2 (en) * 2002-08-20 2004-03-04 Millenium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2015201737B2 (en) * 2003-09-26 2016-09-15 Biontech Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP5089173B2 (ja) * 2005-01-07 2012-12-05 独立行政法人理化学研究所 一塩基多型を用いた炎症性疾患の判定方法
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CA2664567C (en) * 2006-10-04 2016-04-26 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
JP6164759B2 (ja) 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
WO2015140331A2 (en) 2014-03-21 2015-09-24 Haldor Topsøe A/S Gasket free grid modules for catalyst support and a modular system hereof
EP3808775B1 (en) * 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
CN110734925B (zh) * 2018-07-20 2023-04-07 上海市免疫学研究所 一种粒细胞或单核细胞标记系统及其标记方法和应用
WO2021142349A1 (en) * 2020-01-09 2021-07-15 Deka Biosciences, Inc. Method of using genetic markers, snps and/or indels to determine responsiveness to il-10 treatment
EP4547031A1 (en) 2022-06-30 2025-05-07 KMC, Kartoffelmelcentralen, AMBA Starch based gelatine replacement products

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270056A1 (en) * 1986-12-01 1988-06-08 Northwestern University Human LDH-C 4cDNA sequences encoding antigenic regions
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
AU1705397A (en) * 1996-01-16 1997-08-11 Northwestern University Proteins and peptides for contraceptive vaccines and fertility diagnosis
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1999041375A2 (en) * 1998-02-12 1999-08-19 Incyte Pharmaceuticals, Inc. Human receptor proteins
CA2328128A1 (en) * 1998-05-21 1999-11-25 Diadexus Llc A novel method of diagnosing, monitoring, and staging colon cancer
US6440663B1 (en) * 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
WO2001009316A1 (en) * 1999-07-29 2001-02-08 Helix Research Institute Novel genes encoding protein kinase/protein phosphatase
AU6180800A (en) * 1999-07-29 2001-02-19 Chugai Research Institute For Molecular Medicine, Inc. Novel gene participating in the maintenance of smooth muscle cell differentiation
DE19936563A1 (de) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2001229340A1 (en) * 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2417359A1 (en) * 2000-07-28 2002-02-07 Incyte Genomics, Inc. Protein phosphatases
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20070015148A1 (en) * 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US20040058341A1 (en) * 2001-07-26 2004-03-25 Y.Tom Tang Protein phosphatases
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5565375B2 (ja) 2011-05-12 2014-08-06 三菱電機株式会社 入退室管理装置

Also Published As

Publication number Publication date
EP2311861A3 (de) 2011-07-13
IL244596A0 (en) 2016-04-21
EP2277903A2 (de) 2011-01-26
EP2287182A2 (de) 2011-02-23
IL163900A0 (en) 2005-12-18
JP2013055938A (ja) 2013-03-28
EP2314611A3 (de) 2011-07-20
CA2813780C (en) 2019-05-07
JP5756073B2 (ja) 2015-07-29
JP4963778B2 (ja) 2012-06-27
US8716455B2 (en) 2014-05-06
US9453260B2 (en) 2016-09-27
AU2003219045B2 (en) 2008-09-18
EP2311860B1 (de) 2016-09-07
JP2005519608A (ja) 2005-07-07
ES2688186T3 (es) 2018-10-31
EP2314610A3 (de) 2011-07-20
WO2003076631A3 (de) 2004-06-24
US20090081214A1 (en) 2009-03-26
EP2311862A2 (de) 2011-04-20
EP2289910B1 (de) 2018-08-08
JP2010047597A (ja) 2010-03-04
KR20040095283A (ko) 2004-11-12
EP2314612A3 (de) 2011-08-03
IL235085A (en) 2016-06-30
US20090081215A1 (en) 2009-03-26
EP2314610B1 (de) 2015-08-26
EP2332973A3 (de) 2011-09-07
EP2277905A2 (de) 2011-01-26
CA2478413C (en) 2020-03-10
US20170101479A1 (en) 2017-04-13
IL163900A (en) 2015-07-30
EP2277901A3 (de) 2011-05-25
EP2277906A2 (de) 2011-01-26
JP2013172716A (ja) 2013-09-05
US7429461B2 (en) 2008-09-30
EP2277901A2 (de) 2011-01-26
PL215160B1 (pl) 2013-10-31
AU2008258158A8 (en) 2009-01-29
KR20120127536A (ko) 2012-11-21
AU2008258158A1 (en) 2009-01-15
CN105396144B (zh) 2019-08-20
US20130243796A1 (en) 2013-09-19
EP2287182A3 (de) 2011-06-15
EP1483389A2 (de) 2004-12-08
JP2013081462A (ja) 2013-05-09
EP2289910A3 (de) 2011-06-15
US20160002738A1 (en) 2016-01-07
PL373384A1 (en) 2005-08-22
EP2277902A2 (de) 2011-01-26
EP2289910A2 (de) 2011-03-02
US20150031025A1 (en) 2015-01-29
US9637794B2 (en) 2017-05-02
EP2332973A2 (de) 2011-06-15
CN105396144A (zh) 2016-03-16
CN103251952B (zh) 2018-11-09
EP2277904A3 (de) 2011-06-08
CN1646692B (zh) 2015-12-16
WO2003076631A2 (de) 2003-09-18
EP2311861A2 (de) 2011-04-20
ES2685053T3 (es) 2018-10-05
EP2277907A2 (de) 2011-01-26
JP5711711B2 (ja) 2015-05-07
DE10211088A1 (de) 2003-09-25
CA2813780A1 (en) 2003-09-18
MXPA04008867A (es) 2005-06-17
EP1483389B1 (de) 2015-11-04
US20060013817A1 (en) 2006-01-19
CA3035543A1 (en) 2003-09-18
EP2311862A3 (de) 2011-07-13
EP2277905A3 (de) 2011-05-25
EP2287182B1 (de) 2018-08-29
EP2314612A2 (de) 2011-04-27
EP2314610A2 (de) 2011-04-27
KR101261887B1 (ko) 2013-11-06
CA2478413A1 (en) 2003-09-18
CN1646692A (zh) 2005-07-27
EP2314611A2 (de) 2011-04-27
CN103251952A (zh) 2013-08-21
JP5793158B2 (ja) 2015-10-14
US20120014948A1 (en) 2012-01-19
EP2277907A3 (de) 2011-05-25
EP2287181A2 (de) 2011-02-23
EP2277906A3 (de) 2011-05-25
AU2003219045A1 (en) 2003-09-22
EP2311860A2 (de) 2011-04-20
ES2559079T3 (es) 2016-02-10
EP2277904A2 (de) 2011-01-26
EP2277902A3 (de) 2011-05-25
EP2311860A3 (de) 2011-07-20
KR20110026529A (ko) 2011-03-15
CA3035543C (en) 2025-09-23
EP2287181A3 (de) 2011-06-15
KR20110117735A (ko) 2011-10-27
US8551490B2 (en) 2013-10-08
EP2277903A3 (de) 2011-05-25

Similar Documents

Publication Publication Date Title
US9637794B2 (en) Genetic products differentially expressed in tumors and use thereof
CA2538528C (en) Genetic products which are differentially expressed in tumors and use thereof
AU2012216265B2 (en) Genetic products differentially expressed in tumors and use thereof
AU2013206612B2 (en) Identification of surface-associated antigens for tumor diagnosis and therapy
AU2011218666A1 (en) Genetic products which are differentially expressed in tumors and use thereof
HK1154599A (en) Differential in tumour gene products and use of same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 MAR 2016 BY JAMES + WELLS

Effective date: 20130219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2017 BY JAMES + WELLS

Effective date: 20160304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2018 BY JAMES + WELLS

Effective date: 20170308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2019 BY JAMES + WELLS

Effective date: 20180307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2020 BY PAVIS GMBH

Effective date: 20190228

ASS Change of ownership

Owner name: BIONTECH SE, DE

Effective date: 20190709

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2021 BY PAVIS GMBH

Effective date: 20191231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2023 BY PAVIS PAYMENT GMBH

Effective date: 20220303

EXPY Patent expired